Immunotherapy is a cutting-edge form of cancer treatment that is designed to get the body’s own immune system to fight off the disease. Since the immune system is able to discern between diseased cells and healthy ones, this line of treatment is hoped to offer great promise for beating the disease while reducing side effects associated with common interventions. Researchers have made great headway with immunotherapy treatments for some forms of cancer, but the same cannot be said yet for prostate cancer.
Even as immunotherapy options to treat melanoma, bladder and lung cancer have proven successful enough that FDA approval is being sought, prostate cancer remains difficult to tackle in this manner. Researchers, however, say they are continuing efforts to develop a successful approach that might make this option viable and available for helping men beat prostate cancer while reducing side effect potential.
While immunotherapy isn’t an available option for treating prostate cancer at present, men will find this condition is often highly treatable using other methods. Men who are diagnosed with the condition will find that radiation, proton therapy, brachytherapy and other options deliver highly positive outcomes. Precision treatments, such as proton therapy and brachytherapy, are help doctors lower side effect risks while successfully battling cancer cells.
Men who are diagnosed with prostate cancer are urged to discuss all treatment options with their healthcare providers. While an estimated 160,000 American men will be diagnosed with prostate cancer in the coming year, most men will find their condition is highly treatable. Prostate cancer, in fact, has a high survival rate, especially when the disease is detected early. Since all men are at risk for this condition, it is recommended that men talk with their doctors about their personal risks. Even though immunotherapy isn’t an option just yet, doctors have highly effective tools at their disposal to help their patients achieve the best treatment results possible.